Nonhypoglycemic effects of thiazolidinediones

Annals of Internal Medicine

Volumn 134, Issue 1, 2001, Pages 61-71

  Parulkar, A A ^a   Pendergrass, M L ^a   Granda Ayala, R ^a   Lee, T R ^a   Fonseca, V A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BODY WEIGHT DISORDER; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; FIBRINOLYSIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; VASCULAR RESISTANCE;

EID: 0035793135     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-1-200101020-00014     Document Type: Review

References (104)

1. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
2. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes
3. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
4. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
5. PPARγ, the ultimate thrifty gene
6. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects
7. Peroxisome proliferator-activated receptors (PPARS) and their implications in diseases
8. The deadly quartet revisited
9. Banting Lecture 1988. Role of insulin resistance in human disease
10. Cardiovascular risk continuum: Implications of insulin resistance and diabetes
11. Syndrome X: 6 Years later
12. Clinical implications of insulin resistance syndromes
13. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
14. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
15. The metabolic effects of troglitazone in non-insulin dependent diabetes
16. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone
17. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
18. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
19. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients
20. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells
21. Inhibition of oxidation of low density lipoprotein by troglitazone
22. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers
23. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with pglycystic ovary syndrome
24. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
25. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells
26. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism
27. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
28. Peroxisome proliferator-activated receptor-γ, agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
29. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats
30. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
31. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes
32. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
33. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
34. Vasodilatory effects of troglitazone improve blood pressure at rest during mental stress in type 2 diabetes mellitus
35. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery
36. 2+ currents and not endothelial nitric oxide production
37. Macrophages in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPAR activation in mononuclear phagocytes in vitro
38. PPARγ in monocytes: Less pain, any gain?
39. Insulin action enhancement normalises brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes
40. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans
41. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro
42. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells
43. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
44. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation
45. Hyperinsulinemia as an independent risk factor for ischemic heart disease
46. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
47. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes
48. Detection and management of lipid disorders in diabetes
49. Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond
50. Increased susceptibility of LDL cholesterol to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus
51. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B
52. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects
53. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
54. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
55. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
56. Vitamin E supplementation and cardiovascular events in high-risk patients
57. Hypertension in diabetes mellitus
58. Etiology and prevalence of hypertension in diabetic patients
59. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
60. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance Effects of troglitazone
61. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARγ on vascular endothlial function
62. Blood pressure lowering by pioglitazone Evidence for a direct vascular effect
63. Pioglitazone attenuates diet-induced hypertension in rats
64. Effects of pioglitazone on calcium channels in vascular smooth muscle
65. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
66. Insulin-mediated skeletal muscle vasodilatation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release
67. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance
68. Endothelial dysfunction and type 2 diabetes
69. Non-invasive assessment of cardiovascular disease in diabetes mellitus
70. Troglitazone restores endothelium-dependent vasomotion of resistance coronary artery
71. PPAR γ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease
72. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
73. Expression and function of PPARγ in rat and human vascular smooth muscle cells
74. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults
75. The unstable atheroma
76. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
77. Arterial thrombosis and atherosclerosis in diabetes
78. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients
79. Coronary artery disease and fibrinolysis: From the blood to the vessel wall
80. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups
81. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes
82. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus
83. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats
84. The impact of cardiovascular disease on people with diabetes: The potential for prevention
85. Prospective study of microalbuminuria as a predictor of mortality in NIDDM
86. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
87. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance
88. Differentiation and reversal of malignant changes in colon cancer through PPARγ
89. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
90. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
91. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders
92. Troglitazone ameliorates insulin resistance in patients with Werner's syndrome
93. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
94. Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes
95. Troglitazone inhibits progesterone production in porcine granulosa cells
96. An autopsy case of troglitazone-induced fulminant hepatitis
97. Troglitazone-induced hepatic failure leading to liver transplantation A case report
98. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
99. Hepatic failure in a patient taking rosiglitazone
100. Hepatocellular injury in a patient receiving rosiglitazone. A case report